SCHEMBL19769033

SCHEMBL19769033

CC(C)c1ccnc(C=NO)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ HTT P42858 2/20 0.38
▸ GAA P10253 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.35
▸ SLC2A1 P11166 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ TYR P14679 1/20 0.33
▸ TRPA1 O75762 1/20 0.32
▸ PTGS1 P23219 1/20 0.32
▸ CACNA1C Q13936 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ POLB P06746 1/20 0.31
▸ PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6638838 0.76 TYR (0.34) KDM4EALOX15HTTGAAMAPK1
SCHEMBL2904251 0.76 TYR (0.43) KDM4EALOX15HTTGAATYR
SCHEMBL23909426 0.76 KDM4E (0.54) L3MBTL1KDM4EALOX15HTTGAA
SCHEMBL12371005 0.76 HDAC8 (0.37) HTTGAATYRTRPA1PTGS1
SCHEMBL20621292 0.76 CHRNA7 (0.33) HTTGAATYRTRPA1PTGS1
SCHEMBL21645918 0.75 L3MBTL1 (0.54) L3MBTL1KDM4EALOX15HTTGAA
SCHEMBL21645917 0.75 L3MBTL1 (0.54) L3MBTL1KDM4EALOX15HTTGAA
SCHEMBL21866491 0.73 L3MBTL1 (0.51) L3MBTL1KDM4EALOX15HTTHSP90AA1
SCHEMBL21866490 0.73 L3MBTL1 (0.51) L3MBTL1KDM4EALOX15HTTHSP90AA1
SCHEMBL2447598 0.72 L3MBTL1 (0.50) L3MBTL1KDM4EALOX15HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9896432-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2018-02-20 — — US disclosed
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 L3MBTL1 4271/4885KDM4E 4554/4885ALOX15 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback